• Leerink Partners sets a price target of $40 for NASDAQ:IMNM, indicating a potential increase of approximately 76.6%.
• Immunome announces an underwritten public offering aiming to raise $400 million to advance cancer therapy developments.
• The stock price of IMNM has reached a yearly high of $25.30, with today's trading volume hitting 12.54 million shares.

Immunome, Inc. (NASDAQ:IMNM) is a biotechnology company focused on developing innovative cancer therapies. On December 15, 2025, Leerink Partners set a price target of $40 for IMNM, suggesting a potential increase of approximately 76.6% from its current price of $22.65. This optimistic outlook comes as Immunome announces plans for a significant public offering.

Immunome plans to initiate an underwritten public offering of its common stock, aiming to raise $400 million. All shares will be offered directly by the company, and the offering is subject to market conditions. This move could provide Immunome with the capital needed to advance its cancer therapy developments.

The stock price of IMNM has seen a notable increase of 15.74%, with a change of $3.08, reaching a high of $25.30 today. This marks the highest price for the stock over the past year, with the lowest being $5.15. The current market capitalization of IMNM is approximately $2.08 billion.

Today's trading volume for IMNM is 12.54 million shares, indicating strong investor interest. The stock has fluctuated between a low of $21.22 and a high of $25.30 today. Immunome's decision to offer a 30-day option for underwriters to purchase additional shares could further impact its stock performance.

As highlighted by the recent price target set by Leerink Partners, the potential for growth in IMNM's stock is significant. The company's strategic move to raise capital through a public offering aligns with its goal to advance its innovative cancer therapies, potentially driving future stock performance.